Android app on Google Play

Cantor Positive on FDA Approval of ZELTIQ Aesthetics' (ZLTQ) Thigh Area Products; Affirms 'Buy' Rating

April 14, 2014 11:28 AM EDT Send to a Friend
Get Alerts ZLTQ Hot Sheet
Price: $20.24 -5.15%

Rating Summary:
    6 Buy, 2 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 26 | Down: 32 | New: 6
Trade ZLTQ Now!
Join SI Premium – FREE

ZELTIQ Aesthetics, Inc. (Nasdaq: ZLTQ) is positive Monday after the company announced it has received U.S. Food and Drug Administration (FDA) clearance to treat the thigh area with its entire suite of applicators. The CoolSculpting procedure is a clinically proven, non-surgical procedure that reduces fat in the treated area for good, and is already FDA cleared to treat the abdomen and flanks.

Cantor analyst Jeremy Feffer said, Although the FDA approval was delayed somewhat, management does not expect any impact to revenue guidance, and the company remains on track to bring consumable sales to 50% of total revenues in 2014. Despite a more robust competitive landscape in light of Syneron's Ultrashape approval and Valeant's acquisition of Lipsonix, this remains a vastly underpenetrated market with strong utilization trends. We continue to believe that the pieces are in place for upside to management's 20-23% revenue growth guidance for 2014, setting up a 2015 that could be the beginning of sustainable profitability.

Feffer has ZELTIQ at Buy with a price target of $27.

For an analyst ratings summary and ratings history on ZELTIQ Aesthetics click here. For more ratings news on ZELTIQ Aesthetics click here.

Shares of ZELTIQ Aesthetics closed at $16.98 yesterday.





You May Also Be Interested In


Related Categories

Analyst Comments, FDA

Related Entities

Definitive Agreement

Add Your Comment